Literature DB >> 32442059

Multidisciplinary Management of Locoregional Recurrent Breast Cancer.

Thomas A Buchholz1, Sonia Ali2, Kelly K Hunt3.   

Abstract

Entities:  

Mesh：

Year:  2020        PMID： 32442059     DOI： 10.1200/JCO.19.02806

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  4 in total

1.  Spatiotemporal Patterns of Loco-Regional Recurrence After Breast-Conserving Surgery.

Authors:  Fei-Lin Qu; Rui Mao; Zhe-Bin Liu; Cai-Jin Lin; A-Yong Cao; Jiong Wu; Guang-Yu Liu; Ke-Da Yu; Gen-Hong Di; Jun-Jie Li; Zhi-Ming Shao
Journal:  Front Oncol       Date:  2021-08-30       Impact factor: 6.244

2.  Establishment of a tumor immune microenvironment-based molecular classification system of breast cancer for immunotherapy.

Authors:  Xiaobo Zheng; Li Li; Chune Yu; Jiqiao Yang; Yujie Zhao; Chao Su; Jing Yu; Mingqing Xu
Journal:  Aging (Albany NY)       Date:  2021-11-11       Impact factor: 5.682

3.  Prior Local or Systemic Treatment: A Predictive Model Could Guide Clinical Decision-Making for Locoregional Recurrent Breast Cancer.

Authors:  Huai-Liang Wu; Yu-Jie Lu; Jian-Wei Li; Si-Yu Wu; Xiao-Song Chen; Guang-Yu Liu
Journal:  Front Oncol       Date:  2022-02-07       Impact factor: 6.244

4.  Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer.

Authors:  Joyce O'Shaughnessy; Adam Brufsky; Hope S Rugo; Sara M Tolaney; Kevin Punie; Sagar Sardesai; Erika Hamilton; Delphine Loirat; Tiffany Traina; Roberto Leon-Ferre; Sara A Hurvitz; Kevin Kalinsky; Aditya Bardia; Stephanie Henry; Ingrid Mayer; Yanni Zhu; See Phan; Javier Cortés
Journal:  Breast Cancer Res Treat       Date:  2022-05-11       Impact factor: 4.624
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.